309 related articles for article (PubMed ID: 32755654)
41. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia.
Ben-Chetrit E; Eldaim MA; Bar-Meir M; Dodin M; Katz DE
Int J Antimicrob Agents; 2019 Apr; 53(4):423-428. PubMed ID: 30572008
[TBL] [Abstract][Full Text] [Related]
42. [Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms].
Ferrández O; Grau S; Saballs P; Luque S; Terradas R; Salas E
Rev Clin Esp; 2011 Mar; 211(3):119-26. PubMed ID: 21371702
[TBL] [Abstract][Full Text] [Related]
43. Clinical factors predicting persistent carriage of Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae among patients with known carriage.
Kim YK; Song SA; Lee JN; Oh M; Jo KM; Kim HJ; Lee JH; Park J; Jang HJ; Kim HK; Kiem S
J Hosp Infect; 2018 Aug; 99(4):405-412. PubMed ID: 29111353
[TBL] [Abstract][Full Text] [Related]
44. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
[TBL] [Abstract][Full Text] [Related]
45. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
Marimuthu K; Ng OT; Cherng BPZ; Fong RKC; Pada SK; De PP; Ooi ST; Smitasin N; Thoon KC; Krishnan PU; Ang MLT; Chan DSG; Kwa ALH; Deepak RN; Chan YK; Chan YFZ; Huan X; Zaw Linn K; Tee NWS; Tan TY; Koh TH; Lin RTP; Hsu LY; Sengupta S; Paterson DL; Perencevich E; Harbarth S; Teo J; Venkatachalam I;
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383670
[TBL] [Abstract][Full Text] [Related]
46. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
[TBL] [Abstract][Full Text] [Related]
47. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
[TBL] [Abstract][Full Text] [Related]
48. Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia.
Ku NS; Kim YC; Kim MH; Song JE; Oh DH; Ahn JY; Kim SB; Kim HW; Jeong SJ; Han SH; Kim CO; Song YG; Kim JM; Choi JY
Arch Gerontol Geriatr; 2014; 58(1):105-9. PubMed ID: 23988261
[TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
51. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge.
Navarro-San Francisco C; Mora-Rillo M; Romero-Gómez MP; Moreno-Ramos F; Rico-Nieto A; Ruiz-Carrascoso G; Gómez-Gil R; Arribas-López JR; Mingorance J; Paño-Pardo JR
Clin Microbiol Infect; 2013 Feb; 19(2):E72-9. PubMed ID: 23231088
[TBL] [Abstract][Full Text] [Related]
52. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
[TBL] [Abstract][Full Text] [Related]
53. Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.
Cprek JB; Gallagher JC
Antimicrob Agents Chemother; 2016 Jan; 60(1):669-73. PubMed ID: 26552970
[TBL] [Abstract][Full Text] [Related]
54. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
[TBL] [Abstract][Full Text] [Related]
55. Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.
Jacobs DM; Safir MC; Huang D; Minhaj F; Parker A; Rao GG
Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):76. PubMed ID: 29178957
[TBL] [Abstract][Full Text] [Related]
56. External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance.
Machuca I; Gutiérrez-Gutiérrez B; Rivera-Espinar F; Cano A; Gracia-Ahufinger I; Guzman-Puche J; Marfil-Pérez E; Pérez-Nadales E; Castón JJ; Bonomo RA; Carmeli Y; Paterson D; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J;
Int J Antimicrob Agents; 2019 Oct; 54(4):442-448. PubMed ID: 31377343
[TBL] [Abstract][Full Text] [Related]
57. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias.
Micozzi A; Gentile G; Minotti C; Cartoni C; Capria S; Ballarò D; Santilli S; Pacetti E; Grammatico S; Bucaneve G; Foà R
BMC Infect Dis; 2017 Mar; 17(1):203. PubMed ID: 28283020
[TBL] [Abstract][Full Text] [Related]
58. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Apisarnthanarak A; Kiratisin P; Mundy LM
Infect Control Hosp Epidemiol; 2008 Jul; 29(7):671-4. PubMed ID: 18624669
[TBL] [Abstract][Full Text] [Related]
59. Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis.
Kohler PP; Volling C; Green K; Uleryk EM; Shah PS; McGeer A
Infect Control Hosp Epidemiol; 2017 Nov; 38(11):1319-1328. PubMed ID: 28950924
[TBL] [Abstract][Full Text] [Related]
60. Risk factors, outcomes and genotypes of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infection: a three-year retrospective study in a large tertiary hospital in Northern China.
Zheng SH; Cao SJ; Xu H; Feng D; Wan LP; Wang GJ; Xiao XG
Infect Dis (Lond); 2018 Jun; 50(6):443-451. PubMed ID: 29303020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
